靶点- |
作用机制- |
|
|
|
非在研适应症- |
最高研发阶段临床1/2期 |
首次获批国家/地区- |
首次获批日期- |
A Dose Escalation Study of IG3018 to Evaluate the Safety, Tolerability, Efficacy and Pharmacokinetics in Subjects With Hyperuricemia With or Without Chronic Kidney Disease
This is a phase I/II clinical study to evaluate the safety, tolerability, PK, and efficacy of IG3018 tablet in hyperuricemia (HUA) subjects with or without CKD.
100 项与 Intelligem Therapeutics Australia Pty Ltd. 相关的临床结果
0 项与 Intelligem Therapeutics Australia Pty Ltd. 相关的专利(医药)
100 项与 Intelligem Therapeutics Australia Pty Ltd. 相关的药物交易
100 项与 Intelligem Therapeutics Australia Pty Ltd. 相关的转化医学